Append Medical has raised US$4.35 million as part of an extended series A round, which will be used to support the company’s first-in-human trials of Appligator.
Investors include participants from the first tranche of the series A round, as well as new investors, Shoni Health Ventures and ALIVE Israel HealthTech Fund.
Append’s Appligator is in development to be a next-generation, left atrial appendage (LAA) elimination system designed to completely close the LAA—via a transcatheter procedure—without metal implants or sealings. This is intended to eliminate leaking, and, as a result, help reduce the risk of stroke for atrial fibrillation (AF) patients.
“We would like to thank our valued investors for their support,” said Append CEO Nadav Agian. “Today’s news is especially significant because we successfully enlarged the series A second tranche, with both existing as well as new investors. This is indicative of the importance of our work.”
